|Day Low/High||54.23 / 54.80|
|52 Wk Low/High||28.20 / 76.42|
The biotech company plans to commercialize its treatment for AL amyloidosis, a disease that causes protein to build up in the blood.
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders
Trade-Ideas LLC identified Prothena (PRTA) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate
Trade-Ideas LLC identified Prothena (PRTA) as a "dead cat bounce" (down big yesterday but up big today) candidate
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.